Dose rectification of an imbalance between DPP4 and GLP-1 ameliorates chronic stress-related vascular aging and atherosclerosis?
Corresponding Author
Xian Wu Cheng
Department of Cardiology and Heart Center, Yanbian University Hospital, Yanji, Jilin, China
Division of Cardiology, Department of Internal Medicine, Kyung Hee University, Seoul, Republic of Korea
Institute of Innovation for the Future Society, Nagoya University Graduate School of Medicine, Nagoya, Aichi Prefecture, Japan
Correspondence
Xian-Wu Cheng, Department of Cardiology, Yanbian University Hospital, Yanji, Jilin, China.
Email: [email protected]
and
Enze Jin, Department of Cardiology, The Forth Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Email: [email protected]
Search for more papers by this authorMegumi Narisawa
Department of Cardiology, Tajimikenlitsu General Hospital, Tajimi, Gifu Prefecture, Japan
Search for more papers by this authorCorresponding Author
Enze Jin
Department of Cardiology, The Forth Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Correspondence
Xian-Wu Cheng, Department of Cardiology, Yanbian University Hospital, Yanji, Jilin, China.
Email: [email protected]
and
Enze Jin, Department of Cardiology, The Forth Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Email: [email protected]
Search for more papers by this authorChenglin Yu
Department of Cardiology and Heart Center, Yanbian University Hospital, Yanji, Jilin, China
Search for more papers by this authorWenhu Xu
Department of Cardiology and Heart Center, Yanbian University Hospital, Yanji, Jilin, China
Search for more papers by this authorLimei Piao
Department of Cardiology and Heart Center, Yanbian University Hospital, Yanji, Jilin, China
Search for more papers by this authorCorresponding Author
Xian Wu Cheng
Department of Cardiology and Heart Center, Yanbian University Hospital, Yanji, Jilin, China
Division of Cardiology, Department of Internal Medicine, Kyung Hee University, Seoul, Republic of Korea
Institute of Innovation for the Future Society, Nagoya University Graduate School of Medicine, Nagoya, Aichi Prefecture, Japan
Correspondence
Xian-Wu Cheng, Department of Cardiology, Yanbian University Hospital, Yanji, Jilin, China.
Email: [email protected]
and
Enze Jin, Department of Cardiology, The Forth Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Email: [email protected]
Search for more papers by this authorMegumi Narisawa
Department of Cardiology, Tajimikenlitsu General Hospital, Tajimi, Gifu Prefecture, Japan
Search for more papers by this authorCorresponding Author
Enze Jin
Department of Cardiology, The Forth Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Correspondence
Xian-Wu Cheng, Department of Cardiology, Yanbian University Hospital, Yanji, Jilin, China.
Email: [email protected]
and
Enze Jin, Department of Cardiology, The Forth Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Email: [email protected]
Search for more papers by this authorChenglin Yu
Department of Cardiology and Heart Center, Yanbian University Hospital, Yanji, Jilin, China
Search for more papers by this authorWenhu Xu
Department of Cardiology and Heart Center, Yanbian University Hospital, Yanji, Jilin, China
Search for more papers by this authorLimei Piao
Department of Cardiology and Heart Center, Yanbian University Hospital, Yanji, Jilin, China
Search for more papers by this authorSummary
Exposure to psychosocial stress is a risk factor for cardiovascular disease, including vascular aging and regeneration. Dipeptidyl peptidase-4 (DPP-4) exerts many physiological and pharmacological functions by regulating its extremely abundant substrates [eg., glucagon-like peptide-1 (GLP-1), stromal cell-derived factor-1α/C-X-C chemokine receptor type-4, etc.]. Over the past decade, emerging data has revealed unexpected roles for DPP-4 and GLP-1 in intracellular signaling, oxidative stress production, lipid metabolism, cell apoptosis, immune activation, insulin resistance, and inflammation. This mini review focuses on recent findings in this field, highlighting an imbalance between DPP4 and GLP-1 as a potential therapeutic target in the management of vascular aging and atherosclerosis in animals under experimental stress conditions.
REFERENCES
- 1Iso H, Date C, Yamamoto A, et al. Perceived mental stress and mortality from cardiovascular disease among Japanese men and women: the Japan Collaborative cohort study for evaluation of cancer risk sponsored by Monbusho (JACC Study). Circulation. 2002; 106: 1229-1236.
- 2Maingrette F, Dussault S, Dhahri W, et al. Psychological stress impairs ischemia-induced neovascularization: protective effect of fluoxetine. Atherosclerosis. 2015; 241: 569-578.
- 3Chida Y, Steptoe A. The association of anger and hostility with future coronary heart disease: a meta-analytic review of prospective evidence. J Am Coll Cardiol. 2009; 53: 936-946.
- 4Wellenius GA, Mukamal KJ, Kulshreshtha A, Asonganyi S, Mittleman MA. Depressive symptoms and the risk of atherosclerotic progression among patients with coronary artery bypass grafts. Circulation. 2008; 117: 2313-2319.
- 5Arnold SV, Smolderen KG, Buchanan DM, Li Y, Spertus JA. Perceived stress in myocardial infarction: long-term mortality and health status outcomes. J Am Coll Cardiol. 2012; 60: 1756-1763.
- 6Whang W, Davidson KW, Conen D, Tedrow UB, Everett BM, Albert CM. Global psychological distress and risk of atrial fibrillation among women: the women's health study. J Am Heart Assoc. 2012; 1: e001107.
- 7Steptoe A, Kivimaki M. Stress and cardiovascular disease. Nat Rev Cardiol. 2012; 9: 360-370.
- 8Rosengren A, Hawken S, Ounpuu S, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364: 953-962.
- 9Zafar MU, Paz-Yepes M, Shimbo D, et al. Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression. Eur Heart J. 2010; 31: 1573-1582.
- 10Whang W, Kubzansky LD, Kawachi I, et al. Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses’ Health Study. J Am Coll Cardiol. 2009; 53: 950-958.
- 11Tofield A. Myocardial infarction patients are more depressed but receive less antidepressants. Eur Heart J. 2017; 38: 142.
- 12Hayashi M, Takeshita K, Uchida Y, et al. Angiotensin receptor blocker improves a stress-induced prothrombotic state in a murine model. Blood Coagul Fibrinolysis. 2016; 27: 358-360.
- 13Du X, Dong J, Ma C. Is atrial fibrillation a preventable disease? J Am Coll Cardiol. 2017; 69: 1968-1982.
- 14Uchida Y, Takeshita K, Yamamoto K, et al. Stress augments insulin resistance and prothrombotic state: role of visceral adipose-derived monocyte chemoattractant protein-1. Diabetes. 2012; 61: 1552-1561.
- 15Heidt T, Sager HB, Courties G, et al. Chronic variable stress activates hematopoietic stem cells. Nat Med. 2014; 20: 754-758.
- 16Hayashi M, Takeshita K, Uchida Y, et al. Angiotensin II receptor blocker ameliorates stress-induced adipose tissue inflammation and insulin resistance. PLoS One. 2014; 9: e116163.
- 17Yisireyili M, Takeshita K, Hayashi M, et al. Dipeptidyl peptidase- IV inhibitor alogliptin improves stress-induced insulin resistance and prothrombotic state in a murine model. Psychoneuroendocrinology. 2016; 73: 186-195.
- 18Yisireyili M, Hayashi M, Wu H, et al. Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice. Sci Rep. 2017; 7: 1266.
- 19Lei Y, Hu L, Yang G, Piao L, Jin M, Cheng X. Dipeptidyl peptidase-IV inhibition for the treatment of cardiovascular disease- recent insights focusing on angiogenesis and neovascularization. Circ J. 2017; 81: 770-776.
- 20Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369: 1317-1326.
- 21Yang G, Li Y, Cui L, et al. Increased plasma dipeptidyl peptidase-4 activities in patients with coronary artery disease. PLoS One. 2016; 11: e0163027.
- 22Zhu E, Hu L, Wu H, et al. Dipeptidyl peptidase-4 regulates hematopoietic stem cell activation in response to chronic stress. J Am Heart Assoc. 2017; 6: e00639.
- 23Lei Y, Yang G, Hu L, et al. Increased dipeptidyl peptidase-4 accelerates diet-related vascular aging and atherosclerosis in ApoE-deficient mice under chronic stress. Int J Cardiol. 2017; 243: 420.
- 24Tabas I, Bornfeldt KE. Macrophage phenotype and function in different stages of atherosclerosis. Circ Res. 2016; 118: 653-667.
- 25Lozhkin A, Vendrov AE, Pan H, Wickline SA, Madamanchi NR, Runge MS. NADPH oxidase 4 regulates vascular inflammation in aging and atherosclerosis. J Mol Cell Cardiol. 2017; 102: 10-21.
- 26Yang G, Lei Y, Inoue A, et al. Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress. Atherosclerosis. 2017; 264: 1-10.
- 27Cheng XW, Huang Z, Kuzuya M, Okumura K, Murohara T. Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. Hypertension 2011; 58: 978-986.
- 28Cheng XW, Shi GP, Kuzuya M, Sasaki T, Okumura K, Murohara T. Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation. 2012; 125: 1551-1562.
- 29Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2016; 36: 2288-2296.
- 30Moon JY, Seo JW, Lee A, et al. The dose-dependent organ-specific effects of a DPP-4 inhibitor on cardiovascular complications in a model of type 2 diabetes. PLoS One. 2016; 11: e0150745.
- 31Lee KH, Cho H, Lee S, et al. Enhanced-autophagy by exenatide mitigates doxorubicin-induced cardiotoxicity. Int J Cardiol. 2017; 232: 40-47.
- 32Mita T, Katakami N, Shiraiwa T, et al. Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the sitagliptin preventive study of intima-media thickness evaluation (SPIKE): a randomized controlled trial. Diabetes Care. 2016; 39: 455-464.
- 33Holman RR, Bethel MA, George J, et al. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. Am Heart J. 2016; 174: 103-110.
